trending Market Intelligence /marketintelligence/en/news-insights/trending/0oCStOLK2lSeSSDY56rVZQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Kobayashi Pharmaceutical fiscal Q4 profit falls YOY

Complying with International Financial Reporting Standard IFRS 9

Industries Most and Least Impacted by COVID-19 from a Probability of Default Perspective – September 2020 Update

Simplifying The Assessment of Company Fundamental Data

Infrastructure Issues: Understanding and Mitigating Risks


Kobayashi Pharmaceutical fiscal Q4 profit falls YOY

4237919 said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥23.74 per share, a decrease from ¥24.88 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥1.93 billion, a decline of 5.1% from ¥2.04 billion in the prior-year period.

The normalized profit margin fell to 6.2% from 6.5% in the year-earlier period.

Total revenue decreased on an annual basis to ¥31.19 billion from ¥31.57 billion, and total operating expenses declined on an annual basis to ¥28.22 billion from ¥28.51 billion.

Reported net income decreased 13.7% from the prior-year period to ¥1.78 billion, or ¥21.81 per share, from ¥2.06 billion, or ¥25.13 per share.

For the year, the company's normalized net income totaled ¥144.49 per share, compared with ¥143.25 per share in the prior year.

Normalized net income was ¥11.78 billion, compared with ¥11.73 billion in the prior year.

Full-year total revenue totaled ¥128.34 billion, compared with ¥127.29 billion in the prior year, and total operating expenses grew on an annual basis to ¥110.43 billion from ¥109.17 billion.

The company said reported net income rose on an annual basis to ¥12.45 billion, or ¥152.72 per share, in the full year, from ¥12.31 billion, or ¥150.28 per share.

s of June 26, US$1 was equivalent to ¥123.96.Kobayashi Pharmaceutical Co. Ltd.

4237919 said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥23.74 per share, a decrease from ¥24.88 per share in the year-earlier period.